Monoclonal antibodies are laboratory-made proteins that can be given as treatment to aid the immune system’s ability to prevent or minimize infections by germs such as viruses. REGEN-COV (casirivimab/imdevimab) is a monoclonal antibody therapy that binds to the spike protein of the SARS-CoV-2 (the virus which causes COVID-19) and prevents the virus’ attachment and entry into human cells. REGEN-COV can prevent COVID-19, or make its symptom course more mild.
REGEN-COV can be used to treat high-risk patients who:
- have mild or moderate COVID-19 OR
- have close contact to a confirmed case of COVID-19 but are not yet sick
The FDA has issued an Emergency Use Authorization (EUA) for REGEN-COV treatment for COVID-19 in patients with mild to moderate symptoms that are at high risk for progression to severe COVID-19 and/or hospitalization. The FDA has also authorized its use to prevent disease in people who have been exposed to the SARS-CoV-2 virus who have not yet developed symptoms but are at high risk for severe COVID-19. Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19. Monoclonal antibodies are not authorized for use in hospitalized patients.
Monoclonal Antibody Treatment Options in Orange County
Monoclonal Antibody Treatment is accessible in many locations throughout Orange County for eligible, high risk patients:
- Your primary care provider may be able to refer you to receive an infusion through your health care plan.
- Many Emergency Departments and Infusion Clinics offer monoclonal antibody.
Locations which may offer monoclonal antibody infusions are listed here:
Patients or providers should contact the facility to ensure the availability of monoclonal antibody treatment at that site.